A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

AstraZeneca has gained approval from the European Commission for its oral therapy, Tagrisso (osimertinib), to treat adults with NSCLC.

PF-07976016 is under development for the treatment of obesity. It is administered as oral solution and oral suspension. The drug candidate acts by targeting gastric inhibitory peptide (GIPR).

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

StemVacs-V is under clinical development by Res Nova Bio and currently in Phase II for Metastatic Breast Cancer.

Prexigebersen is under clinical development by Bio-Path and currently in Phase II for Relapsed Acute Myeloid Leukemia.

CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE).

AST-006 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase I for Breast Cancer.

Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure.

Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome).